Chris Storgard

Medicine · Health Sciences

18h-index2.2kcitations46works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gout, Hyperuricemia, Uric Acid(22), Urticaria and Related Conditions(10), Heat shock proteins research(9), Case Reports on Hematomas(8), Hepatitis C virus research(5)

Publications46 total

Data from Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors
2023Open Access
Data from Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors
2023Open Access
In Vivo Persistence and Function of Adaptive NK Cell Infusions (FATE-NK100) from CMV Seropositive Haploidentical Related Donors
Biology of Blood and Marrow Transplantation·2019· 5 citedOpen Access
Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 Data
Blood·2018· 1 cited
Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study
Lara D. Veeken·2017· 113 citedOpen Access
Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial
Arthritis & Rheumatology·2017· 150 citedOpen Access
Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)
Annals of the Rheumatic Diseases·2016· 161 citedOpen Access
Lesinurad Combined With Allopurinol: A Randomized, Double‐Blind, Placebo‐Controlled Study in Gout Patients With an Inadequate Response to Standard‐of‐Care Allopurinol (a US‐Based Study)
Arthritis & Rheumatology·2016· 174 citedOpen Access
THU0537 Clinical Response of Tophus and Flares To Extended Use of Lesinurad in Combination with A Xanthine Oxidase Inhibitor in Patients with Gout
Annals of the Rheumatic Diseases·2016· 6 cited
THU0495 Examination of Serum Uric Acid (Sua) Lowering and Safety with Extended Treatment with Lesinurad and Allopurinol in Subjects with Gout
Annals of the Rheumatic Diseases·2016· 5 cited
Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis
Advances in Therapy·2016· 18 citedOpen Access
Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis
Rheumatology and Therapy·2016· 6 citedOpen Access
Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol
Annals of the Rheumatic Diseases·2016· 98 citedOpen Access
A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift
Postgraduate Medicine·2015· 32 cited
Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males
Drug Design Development and Therapy·2015· 55 citedOpen Access
SAT0307 Lesinurad Monotherapy in Gout Patients Intolerant to Xanthine Oxidase Inhibitors (Light): A Randomized, Double-Blind, Placebo-Controlled, 6-Month Phase III Clinical Trial
Annals of the Rheumatic Diseases·2015· 5 cited
FRI0333 Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination with Allopurinol: Results from a Phase III Study in Gout Patients Having an Inadequate Response to Standard of Care (Clear 2)
Annals of the Rheumatic Diseases·2015· 9 cited
SAT0329 Lesinurad, A Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout: the Crystal Phase III Clinical Trial
Annals of the Rheumatic Diseases·2015· 16 cited
page 1 of 3Next →

Frequent Co-authors

Scott Baumgartner(13), Maple M. Fung(10), Jeff Kopicko(9), Nihar Bhakta(9), Razelle Kurzrock(8), Robert Morlock(8), Scott Adler(7), Nicola Dalbeth(7), David S. Hong(7), Naveen Dakappagari(6), Lee S. Rosen(6), Kenneth G. Saag(5), Fernando Pérez-Ruiz(5), Rabih Said(5), Gerald S. Falchook(5), Aung Naing(5), Apostolia M. Tsimberidou(5), Gerald R. Galluppi(5), Dwayne G. Stupack(4), Michael A. Becker(4)